腭扁桃体非霍奇金淋巴瘤70例临床分析

Clinical analysis of non-Hodgkin lymphoma of palatine tonsil-Report of 70 cases

目的探讨原发于腭扁桃体的非霍奇金淋巴瘤(NHL)的临床疗效及其预后因素。方法回顾性分析1993年11月至1999年8月收治的70例原发于腭扁桃体的NHL的临床资料。根据Ann Arbor分期,Ⅰ期12例,Ⅱ期39例,Ⅲ期15例,Ⅳ期4例。根据1981年国际工作分类:低度恶性8例,中度恶性28例,高度恶性34例。单纯化疗组30例,单纯放疗组3例,综合治疗组37例。结果全组总体生存率为56.3%,其中1、3、5年生存率分别为82.5%、67.3%、58.5%。高度恶性患者单纯化疗、单纯放疗、综合治疗的总体生存率分别为20.0%、0、52.6%(P<0.05)。多因素分析证明,病理类型和近期疗效是影响预后的独立因素。结论放化疗综合治疗可提高腭扁桃体NHL的疗效,病理类型和近期疗效是腭扁桃体NHL重要的预后因素。

Objective To investigate the treatment method and prognostic factors of patients with non-Hodgkin lymphoma(NHL)of palatine tonsil.Methods 70 patients with NHL of palatine tonsil were re- viewed.According to Ann Arbor staging classification,12 patients had stageⅠ,39 stageⅡ,15 stageⅢand 4 stageⅣ.Working formulation was used in pathologic classification which was low grade 8 cases,intermedi- ate grade 28 cases and high grade 34 cases.30 cases were treated by chemotherapy alone,3 cases by radio- therapy alone,37 cases by chemotherapy and radiotherapy.Results The overall survival rate was 56.3%. They were 82.5% in 1 year,67.3% in 2 years and 58.5% in 5 years,respectively.The overall survival rates in high grade cases of pathologic classification were 20.0% in chemotherapy alone,0 in radiotherapy alone, 52.6% in chemotherapy and radiotherapy(P<0.05),respectively.Multivariate analysis showed that the pathologic classification and tumor regressive condition were independent prognostic factors.Conclusion Combined modality therapy significantly improves the overall survival rate in non-Hodgkin lymphoma(NHL)of palatine tonsil.The pathologic classification and tumor regressive condition are the important prognostic fac- tors of patients with NHL of the tonsil.